Jim Robinson is a respected and proven health care executive and passionate leader who was named president of Astellas Americas on April 1, 2016. In this role, Robinson is responsible for the company’s growing operations in North and South America. Prior to this promotion, Robinson led the company’s pharmaceutical commercial organization in the U.S., a role that he held since 2013. Robinson is also the executive sponsor of Astellas' African American employee resource group.

Robinson’s nearly 25-year career spans a variety of diverse disciplines within the health care industry, including sales, marketing, new product planning, market access, reimbursement, state government affairs and managed markets. He joined Astellas in 2005 as vice president of health systems. Robinson has led commercial efforts in a wide range of therapeutic areas throughout his career, including virology, oncology, cardiovascular, urology, dermatology and anti-infectives.

Prior to joining Astellas, he served as an executive at the former Schering-Plough Corporation, which was acquired by Merck & Company in 2009. Beginning his career as a sales representative in 1992, he quickly advanced through the corporation, rising to vice president in charge of hepatitis sales and managed care. In this position, Robinson led the largest specialty pharmaceutical sales division within Schering-Plough.

Robinson contributes his vision and expertise to the pharmaceutical industry and the business community by serving on several boards, including the Pharmaceutical Research and Manufacturers of America (PhRMA) Board of Directors. He also serves as chairman of the PhRMA State Committee, providing direction on the trade association’s state-level policy and legislative priorities, and sits on the Board of the Executive’s Committee. Robinson is a member of The Commercial Club of Chicago and serves on the BioScience Council for ChicagoNEXT, a private-public partnership dedicated to expanding Chicago’s business climate and driving growth and opportunity in science, technology, innovation and entrepreneurship. Robinson is a founding member and serves on the board of directors of MATTER, a group of leaders passionate about creating products and services that advance the healthcare industry. He is also on the Board of Directors for the Chicago Botanic Garden. 

Robinson is a graduate of DePaul University, Chicago, Illinois.  A native of Skokie, Illinois, Robinson currently resides in Kenilworth, Illinois.

Fabrice Chouraqui is currently working as President of Novartis Pharmaceuticals Corporation.

Fabrice has 20 years of experience in the Pharmaceutical industry, having worked in Research & Development, Commercial and General Management positions in Europe, North America, Asia and Latin America. Prior to joining Novartis in 2010, Fabrice worked for Bristol-Myers Squibb and Hoechst Marion Roussel.

Fabrice holds a Master in Science and a Doctorate in Pharmacy from the University of Paris as well as an MBA degree from INSEAD.

Paul Navarre is the Chief Executive Officer of Ferring Holding Inc., the U.S. subsidiary of Ferring Pharmaceuticals (The Ferring Group). Ferring Holding Inc. has more than 800 employees and turnover of over $700M.

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. Ferring identifies, develops and markets innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology, women’s health and orthopaedics.

An accomplished senior executive, Mr. Navarre has built a track record of success spanning 25 years including experience in fast-moving consumer goods and pharmaceuticals. He has served in key strategic positions responsible for operations in Europe, Asia, Africa, Middle East and the U.S. A French national, he has lived and worked in France, Italy, the UK, Switzerland and the U.S.A.

Before joining Ferring, Mr. Navarre was President of International Operations for Allergan. He began his career at Procter and Gamble where over 15 years he held multiple leadership positions in the company’s consumer goods and pharmaceuticals divisions.

Mr. Navarre has solid track record of delivering top line growth in the specialty pharmaceutical business through commercial innovation and customer centric approaches. He is recognized as an authentic visionary leader with the ability to attract and manage multi-functional talents.

Mr. Navarre and his wife have been married for 23 years. They have 4 children and live in New York.

Sue Mahony, Ph.D., became president of Lilly Oncology in March 2011. She is also a senior vice president for Eli Lilly and Company and a member of the company’s executive committee.

In May 2009, she was appointed senior vice president, human resources and diversity for Lilly. Previously, she led Lilly’s operations in Canada.

Mahony was born and educated in the United Kingdom, where she obtained a Bachelor of Science degree in pharmacy from Aston University in Great Britain. She obtained a Ph.D. in pharmacy in the Cancer Research Campaign Experimental Chemotherapy Group also at Aston University, and a master’s degree in business

administration from the London School of Business. In 2012, Sue received an honorary doctorate from Aston University.

Mahony joined Lilly in 2000 after more than a decade in sales and marketing roles in the United Kingdom and Europe for Schering-Plough, Amgen and Bristol-Myers Squibb. Since joining Lilly, Mahony has held executive leadership roles in product development, six sigma, human resources and general management, with global and operational responsibilities for North America, Europe, Japan and China.

In 2010, Mahony was recognized as one of the Indianapolis Business Journal’s “Women of Influence.” Mahony served on the board of the United Way of Central Indiana from 2010 to 2012 and has served on the Board of Directors of Park Tudor School since 2015. In December 2017, Mahony joined the Board of Directors of Assembly Biosciences, Inc.

Sue and her husband, John, have two children: Thomas and Rebecca.

Stephen Ubl is president and chief executive officer of Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America's leading biopharmaceutical research companies. Mr. Ubl leads PhRMA's work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery, and access to life-saving medicines. If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl," the New York Times' Robert Pear wrote in February 2016. "He is more conversant with the intricacies of health policy, and more adept at the politics." He is routinely recognized as one of Washington’s most effective advocates, and, in 2017, was named for the second year in a row to Modern Healthcare’s “100 Most Influential People in Healthcare.” In 2016, he was named a Top Lobbyist by The Hill and a top health influencer by Medical Marketing & Media and PR Week magazines.

Bharat Tewarie joins UCB with 27 years of experience in the pharma and biotech industry. He has acquired impressive worldwide expertise while leading global business unit teams to great success. His past experience in domains such as immunology and neurology are a great match to UCB’s core focus areas. His knowledge of markets around the world is also key to helping UCB prepare for future product launches. Trained as a medical doctor (MD), Bharat Tewarie also has an extensive background in multiple aspects of pharmaceutical management, including P&L responsibility, business development, sales, global marketing, clinical research and medical affairs. He has dedicated his career to better understanding patients living with chronic diseases and how to best meet their needs. At UCB Bharat heads the Global Strategic Marketing Practice and is a member of the Executive Committee.

Dr Rob Scott is Zimbabwean born and studied medicine at the University of Cape Town. For thirty years Rob has held leadership positions in global Pharma, starting with J&J in South Africa. As the Global Head of CV and Metabolic at Pfizer he was responsible for what was then the world’s largest pharmaceutical product and the largest cardiovascular product – Lipitor and Norvasc. As Executive Vice President of R&D at AtheroGenics in Atlanta Georgia, he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech. As Chief Medical Officer and Head of Development of Cerenis Therapeutics in Toulouse, France, Rob advanced the science of synthetic HDL. At Amgen, Rob ran the Cardiovascular, Metabolic, Nephrology, Bone, Inflammation and Neuroscience Therapeutic Areas. He also created the Development Design Center, a Center of Excellence focused on using predictive analytics for designing and implementing clinical trials. Rob is currently the Chief Medical Officer and Head of Development at Abbvie. In this role, he is a board member of Transcelerate and a member of the PhRMA Biomedical Advisory Committee. Rob was a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 to 2016 and also served on the Endocrine and Metabolic Advisory Committee. Rob has been involved with every therapeutic area and mode of drug delivery as well as both small molecules and biologics.  He invented and developed the first drug combination to simultaneously treat two different disease states - Caduet.

Bob managed a $6B P&L at Otsuka while managing a diverse and growing product portfolio across the cardio-renal, neuroscience, oncology, and medical device markets. Having compiled more than 25 years of experience in the pharmaceutical industry, across commercial and general management roles for premium companies within industry he was instrumental in building ABILIFY®, Abilify Maintena®, SAMSCA®, SPRYCEL® and Rexulti®. As Vice President and Global Business Manager for Oncology at Wyeth,  he led the global launch of Torisel for RCC and later assumed responsibility for U.S. Commercial Operations. Bob began his career in pharmaceuticals with Johnson & Johnson where he held positions of increasing responsibility. During his tenure at Otsuka Bob held senior level executive roles including President & COO for North America and most recently Bob was in the role of President & CEO of Otsuka America Pharmaceuticals, Inc. He currently maintains the position of Board Chairman for Otsuka Canada. Bob is also Executive Advisor and a member of the Board of Directors for Hyalo Technologies; as well as Board Member of Neurotez both Biotech start ups. Previously Bob served on the board of Immunomedics a publicly traded company focused on Oncology.

Dr. Zhen Su, Senior Vice President and Chief Medical Officer of North America for EMD Serono and Head of Global Medical Affairs Oncology (a.i.), heads the North American Medical Affairs organization as well as the medical strategy development and global medical team for the Oncology Franchise.

A physician executive with more than 20 years of experience, Dr. Su has strong clinical expertise in oncology, immuno-oncology and urology. He has held positions in academic and pharmaceutical medicine, including general management, clinical development, medical affairs and business development. Prior to EMD Serono, Dr. Su served in numerous leadership positions at Sanofi and GSK. Before joining industry, Dr. Su held several academic positions, including faculty roles at Duke University and University of Florida.

He has deep ties to the oncology community, having worked with leading oncologists at organizations globally. Dr. Su earned his MD degree from the Technical University of Dresden, Germany and completed his MBA training at the University of Toronto, Canada.

Bill Nolan has more than 25 years of healthcare and pharmaceutical marketing, product management, and healthcare administration experience and is currently vice president and general manager of the RA&SS, MPRS and Biologics HUB with McKesson Specialty Health. Bill joined McKesson in 2004.

Prior to joining McKesson, Bill spent nearly six years with Merck & Company in various management roles in the Economic Affairs and Managed Care areas. He was active in product marketing, oversaw the Merck Patient Assistance Programs portfolio, managed patient and physician reimbursement services, and successfully represented Merck before state and federal legislators, third-party organizations and lobbyists to advance a favorable public policy environment for Merck and the pharmaceutical industry.

Prior to his tenure at Merck, Bill was the Medicare HMO Product Director for four years with Aetna US Healthcare, Inc. Bill began his healthcare career as a nursing home administrator in Pennsylvania, where he oversaw a 120-bed skilled nursing and rehabilitation center.

Bill holds a Licensed Nursing Home Administrator degree from the Commonwealth of Pennsylvania and Temple University, as well as a bachelor’s degree in Psychology from West Chester University.

Glenn Wada is President of CoverMyMeds.  As President, Glenn is responsible for driving the company’s overall sales and operational performance.  He brings enterprise expertise to the CoverMyMeds Executive Leadership Team, with a focus on delivering significant value to our global pharmaceutical manufacturer, health plan, pharmacy, provider and clinical system customers and partners. 

Prior to joining CoverMyMeds, Glenn Wada spent a decade as a senior executive at global enterprise software provider, SAP, running a number of their large, multi-billion dollar business units.  He also worked at EY, PeopleSoft, and several pharmaceutical & healthcare industry companies – helping those companies to innovate and grow while driving exponential growth. 

Glenn has served as a Board Member for Special Olympics of Pennsylvania, on the Executive Committee for The Haverford School in Pennsylvania, and is eager to find similar civic / philanthropic opportunities in Columbus. 

Currently Moderna’s Chief Digital Officer, Marcelo has a wealth of experience in both tech companies and Life Science companies and a true passion for making Digital a reality. He has 20-years experience working in the IT field, with the last 10 years being spent in leadership roles for multinational companies in Europe and tin the U.S. Prior to joining Moderna Therapeutics, Marcello has been instrumental in conceiving and building creative IT solutions to help solve business challengers, first at Motorola and then at bioMerieux and now at Moderna Therapeutics. His expertise is in visioning, strategizing and implementing innovative programs to update and streamline the digital landscapes.  He is known for his ability to transform a company’s Information flow, and ultimately improving the product and the company’s processes through digitization.

Mr. Damiani possesses a Master of Science degree in Information Systems Architecture from the University of Toulouse in France, and an international Executive MBA through TRIUM, an alliance of three of the world’s top universities: the London School of Economics, New York University Stern Business School and the HEC School of Management in Paris.

Hensley Evans is a principal in ZS’s New York office and is the leader of ZS’s consumer and patient marketing practice. Hensley has worked with many of the world’s top healthcare, biopharmaceutical and consumer packaged goods brands to offer strategic direction and insight.

There are several words to describe Dr. Christopher Boone: health futurist, patient advocate, executive, professor, social scientist, and self-proclaimed “data hippie.” Boone is recognized as being a dynamic, innovative thought leader and a public voice on the power of health data and its ability to radically change the U.S. health care delivery system. Most recently, he was honored as a 2017 40 Under 40 Leader in Minority Health by the National Minority Quality Forum and Congressional Black Caucus.

Boone currently serves as the Vice President of Real World Data & Analytics at Pfizer, an adjunct professor in the health informatics program at the University of Cincinnati, and a co-founder of a few start-up companies. Prior to Pfizer, he was a Vice President at Avalere Health and the Executive Director/CEO of the Health Data Consortium (HDC), a public-private partnership working to build a national movement on the use of open health data to transform the U.S. health care system.

Boone has held appointments on several prominent national committees, including the Executive Board of Directors for the Patient Advocate Foundation and the National Patient Advocate Foundation, the National Quality Forum’s (NQF) Interoperability Committee, the advisory group for Robert Wood Johnson Foundation’s Data Across Sector for Health (DASH) initiative, the Board of Directors for SHARE for Cures, the Federal Health IT Policy Committee, the advisory group for the American Society of Clinical Oncologists CancerLinQ initiative, and the National Committee on Vital and Health Statistics Working Group on HHS Data Access and Use.

Originally from Dallas, Texas, Dr. Boone earned a B.S. from the University of Tulsa, a M.S. from the University of Texas at Arlington, a PhD from the University of Texas at Dallas, and two executive certificates from the Harvard Kennedy School. In addition, he is a certified healthcare executive and Fellow of the American College of Healthcare Executives.

Andrew Thompson is Co-Founder, President and Chief Executive Officer of Proteus Digital Health. His vision for digital medicine is focused on expanding global access to care, dramatically increasing the value delivered by drugs and creating a more sustainable model for innovation that leverages the mobile device in everyone's pocket.

He is also a Co-Founder and Board Member of Summit Schools, a leading Charter School organization with an acclaimed track record and unique digital platform, featured in the Davis Guggenheim movie “Waiting for Superman”.

Thompson is active in digital humanities innovation as a Member of the Stanford University Libraries and Academic Information Resources Council and with Cambridge University. He is a Co-Founder of Parker Library Online - a leading destination for digital medieval studies.

He holds master’s degrees in Engineering (Cambridge), Education (Stanford) and Business (Stanford GSB) and has a successful 25 year track record starting and building technology-based healthcare companies in Silicon Valley.

Rolf Benirschke’s third season as a placekicker in the NFL was cut short when he collapsed on a cross-country team flight while battling ulcerative colitis. He would undergo two emergency surgeries within six days and his life would hang in the balance for the six weeks he remained in the intensive care unit. After surviving, he made a miraculous comeback to play seven more seasons with the San Diego Chargers, becoming the first player ever to wear an ostomy bag in the NFL. He would earn numerous honors including being named the Walter Payton NFL Man of the Year, NFL Comeback Player of the Year, play in the Pro Bowl and be inducted into the Chargers Hall of Fame.

Following his NFL career, Rolf became CEO of Legacy Health Strategies, a patient engagement company, and founded The Grateful Patient Project. He is now a respected leader and speaker in the health care industry and works tirelessly as a patient advocate who is active in supporting legislation that encourages research and innovation and protects patients.

Rolf enjoys working with organizations that have a heart for patients like UCSD Health, the Crohn’s & Colitis Foundation, San Diego Blood Bank, and numerous other charities. He takes time out of his busy schedule to connect personally with patients who need encouragement, especially those living with Inflammatory Bowel Disease (IBD).

He is also the founder of the Rolf Benirschke Legacy Foundation and the author of three books, including his autobiography, Alive & Kicking. Rolf has been married for 28 years to the love of his life, Mary, and they have four children, three of whom have special needs.

Amy Gutierrez, Pharm.D., joined Kaiser Permanente as Vice President and Chief Pharmacy Officer in March 2017. She provides leadership and direction for KP’s $9 billion clinical and pharmacy operations to drive improvements in outcomes, member experience, affordability, standardization and regulatory compliance.

Amy came to KP after a 32-year career with the Los Angeles County Department of Health Services, including serving as chief pharmacy officer, leading all pharmacy operations for the nation’s second largest public health system. Amy also served as hospital pharmacy director for the Los Angeles County LAC+USC Medical Center.

Amy’s expertise includes broad experience in pharmacy operations, medication management and regulatory compliance, including

strength in interpretation and compliance with CMS, State Board of Pharmacy, Joint Commission, State Title 22, USP sterile compounding regulations, and HRSA 340B standards. Since 2013, Amy has been a member of the California State Board of Pharmacy, appointed by Governor Brown in 2012. Amy is currently serving as the Board of Pharmacy’s president, a role she assumed in 2015.

Amy earned her doctor of pharmacy degree from the University of Southern California (USC), and completed a California Healthcare Foundation healthcare leadership fellowship In conjunction with UC San Francisco. She is an adjunct professor at both USC’s and Western University’s schools of pharmacy and has served as a Leadership Advisor for the California Healthcare Foundation Leadership Fellowship Program.

Cheryl MacDiarmid is a member of the senior executive team in the US for GSK, a leading, multinational global pharmaceutical company. She is directly responsible for the US primary care sales division; strategy, planning and operations; and marketing, leading more than 2500 employees. A dynamic and strategic general manager, Cheryl brings 20 years of deep experience in building businesses in the US and Canada across sales, marketing and managed markets in both pharmaceuticals and vaccines. 

She has a gift for creating and leading extraordinarily powerful teams. She seeks out and thrives on challenge, leading her teams to set an ambition, make choices and execute bold, game-changing moves that pivot and change a business trajectory. Notable recent accomplishments include catalyzing a significant turnaround within the US sales organization while solidifying a path to sustained growth and launching a new type 2 diabetes medicine in the US, exceeding external benchmarks and market expectations. 

She is a values-driven leader with significant experience managing commercial risk, compliance and alliance governance. As a pharmacist, Cheryl navigates complex scientific and clinical data with ease and has a passion for respiratory disease and diabetes. She brings a global mindset to her work, having served as a chief of staff associate to the GSK President, International Region.

A native of Canada, Cheryl graduated from the University of Toronto with a degree in Pharmacy and subsequently received an MBA from the Schulich School of Business. She lives in Philadelphia. Her personal passions include running, skiing, and visits north to Canada. 

David Blair is Head of Industry for Health at Google. He leads a team

that provides thought leadership, digital marketing strategies, insights,

and cross-platform advertising solutions utilizing Google’s search, content network, YouTube, mobile, programmatic and analytics platforms for the world’s leading pharmaceutical and consumer health companies. Prior to Google, David was General Manager/SVP of Provider Solutions at Everyday Health.

David began his digital career in 1997 at iVillage as Vice President of Strategic Sponsorships where he pioneered many of the first digital marketing initiatives with Fortune 500 companies including P&G, Coke, Ford, Kimberly Clark, Kellogg’s

and Fuji Film. He moved into the digital health space in 2001 as SVP/Group Publisher for Johnson & Johnson’s BabyCenter.com and was SVP of Ad Sales for Revolution Health, before the merger with Everyday Health in 2008. Blair serves on the Google Healthcare Advisory Board, was named one of the top 40 Healthcare Transformers in the US by Medical Marketing & Media in 2015 and was a juror for

the 2016 Clio Health Awards. He is a frequent keynote speaker at major agencies and industry events, most recently the IMCAS World Congress; Cannes Lions Health, American Heart Association, and Cleveland Clinic’s Patient Experience Summit.

Tolga Tanguler is the Regional President, North America for Rare Diseases at Pfizer. In this role, Tolga leads an organization of more than 200 colleagues across marketing, sales, access, medical and corporate affairs and a portfolio of 6 assets to ensure they are focused on one objective: to transform patient’s lives. A key focus is to ensure that the engagement and experience of rare disease patients and their families are at the forefront of all programs; while ensuring the organization is prepared for the next phase of scientific breakthroughs, including gene therapy. Tolga has more than 15 years of experience in the global pharmaceutical industry, including leadership roles in both developed markets such as the US, Japan and the Nordics and emerging economies including Africa/Middle East and Latin America. Most recently, Tolga was the Vice President, Global Marketing for ELIQUIS. Throughout these various assignments, the organizations led by Tolga were recognized for their rapid growth performance, as well as their strong culture that led to a significant improvement in colleague engagement.  Tolga has Bachelor of Science degrees in Economics & Finance from University of Istanbul, and a Masters of Business Administration in Marketing and Supply Chain from Michigan State University. He also has a

Post Graduate Degree in Marketing from the University of California. Tolga was recently appointed as a member of the Board of Directors of the National Association of Specialty Pharmacy.

Bozidar Jovicevic is a Global Head of Digital Medicines at Sanofi, in charge for beyond-the-drug initiatives. He is MD/MBA by training and during the first part of his career he spent 12 years at Novartis in various sales and marketing roles, launching two multi-billion dollar products on a regional and global level. He then moved to a medical function where he orchestrated transformation of multichannel engagement with HCPs through building VivindaTV, a global eCongress platform dubbed as - Netflix of medical conferences - (currently available in 104 countries). Bozidar is highly entrepreneurial (founded three startups), loves playing chess (used to play semi-professionally) and is passionate about the science of human behaviour and peak performance.

Wendy Mayer is Vice President of Strategy, Pfizer Innovative Health, responsible for advising and tracking the development and execution of the business strategy for Pfizer’s innovative business. Since joining Pfizer in 1997 Wendy has had various roles across the organization including VP of Worldwide Innovation, Connecticut State Director for Primary Care, VP Clinical Trial Excellence, and leadership of various Market Analytics teams across the organization. Wendy currently leads Pfizer’s New York Women’s Leadership Network.

Prior to Pfizer, Wendy was a Senior Consultant at Deloitte & Touche Consulting and did an administrative fellowship at Northwestern Memorial Hospital in Chicago. Wendy holds a bachelor’s degree and MBA from Cornell University. She has been identified by Deloitte as a “Women to Watch” in healthcare, she is on the board of advisors at Pulse @MassChallenge digital health accelerator, and is a board member for AWIS (Association for Women in Science).

Rucha Vyas joined the Nokia Digital Health team in 2017 with over 10 years of experience in the population health space. As the Head of Strategy & Business Development at Nokia, Rucha oversees key partnerships and develops effective strategies to implement programs and services to meet the needs of clients. In addition, Rucha provides guidance on the adoption of Nokia offerings within enterprise markets to improve population health management. Rucha has an in depth understanding of the healthcare system with her experience working for health systems, carriers, and employer groups. Prior to joining Nokia, she was a Health and Productivity Consultant at Alliant Employee Benefits where she consulted with employer groups on the design, implementation, and evaluation of their disease management and wellness programs.  

Rucha received her bachelors degree in Political Science from the University of Maryland, Baltimore County (UMBC). She holds a Masters in Public Health from George Washington University and an MBA from Johns Hopkins Carey School of Business with a certificate in the Business of Medicine.  

More information coming soon...

As Vice President of Client Development, Tina brings more than 20 years of experience building business for the life sciences and technology industries. With a robust history in account growth, relationship management, and new business generation, Tina shapes and executes solutions to meet client needs and brand strategies. Having worked in outsourced commercial solutions for over 20 years, Tina has helped pharmaceutical and biotech companies build out their commercial organizations by identifying the right strategy and tactics to drive pre-launch, launch and post-launch brand success in terms of product growth and patient outcomes. This includes developing innovative commercial solutions for customers including Clinical Educators, Medical Science Liaisons, clinical call centers, and sales teams.

Tina obtained her bachelor’s degree in marketing from the State University of New York at Plattsburgh, and her MBA in healthcare administration from Baruch College/Mt. Sinai School of Medicine in New York. Prior to VMS, Tina worked for NDC Health (now Wolters Kluwer) and spent 14 years with inVentiv Health in various business development leadership roles. In her spare time, she also taught pharmaceutical sales force management at Rutgers State University of New Jersey in the school’s pharmaceutical MBA program. Tina was honored as a “Rising Star” by the Healthcare Businesswomen’s Association and has been a member of HBA for over 15 years.

Mr. André Côté holds the position of VP & Chief Operating Officer - Commercial Capabilities and Customer Experience for Eli Lilly Canada Inc. In this role, he is responsible for enhancing the company’s customer facing capabilities, and improving the experience the organization provides for patients, healthcare professionals and payers. Mr. Côté is also a member of the Senior Management Team of Eli Lilly Canada. Since joining Eli Lilly Canada in 1993 as a Sales Representative, Mr. Côté has held a number of progressive roles in Canada within the Sales, Operations, Learning and Development, and Corporate Affairs organizations, including Government and Economic Affairs Manager, Sales & Operations Director for Quebec, as well as Vice President of Sales. Mr. Côté has also held various Global leadership positions at Lilly in Pricing, Reimbursement & Access, as well as Global Brand Marketing Strategy. He was also a member of the Senior Leadership Teams for Global Corporate Affairs, and the Global BioMedicines Business Unit. Most recently, Mr. Côté held the position of Senior Director, Global Customer Support Programs at Lilly Corporate Center in Indianapolis, overseeing corporate strategy and capabilities development within the organization. Prior to joining Eli Lilly Canada, Mr. Côté obtained a Bachelor’s Degree in Business and Marketing in 1993 from the Université Laval in Quebec. Mr. Côté is fluent in both English and French.

Daniel J. Gandor is Director, Digital Innovation and Corporate Program Management for Takeda Pharmaceuticals U.S.A., Inc. In this role, Dan spearheads efforts to identify opportunities for game-changing digital disruption within Takeda’s U.S. business unit in order to ultimately better support and activate patients in managing their diseases and treatments. He also leads large cross-functional corporate initiatives and programs across the U.S. business unit. 

Dan has a BA in Biology and Environmental Science from Northwestern University, and returned to the Kellogg School of Management for an MBA in marketing, technology management, and biotechnology management.  He has been with Takeda since 2006, serving in numerous commercial and leadership roles. Dan can be found on LinkedIn, Twitter (@DanGandor), and DanGandor.com. 

Jim O’Donoghue is head of S3 Connected Health.  He has 30 years’ experience in designing and delivering innovative services and solutions across healthcare, consumer and communications sectors.

Over the past 12 years Jim and his team have designed digital patient support solutions for Pharma and Healthcare Providers that are available across 40 countries, including the largest telehealth program in the UK, and the largest chronic disease management program in Europe.

Jim serves a on the industry steering committee for the Applied Research Centre for Connected Health and served on the industry board for the UK “3 Million Lives” program.

Ms. Zaim is the global head for Alzheimer’s Disease (AD) at Eisai where she develops strategies to progress the commercial development of Eisai's existing and future AD assets and heads the collaborative efforts of internal and external stakeholders to maximize the value of the AD portfolio. She also leads Eisai's Neurology Commercial Development team in creating and driving commercial strategies for other neurology early pipeline assets and late stage compounds approaching the commercialization stage. Prior to joining Eisai in April 2016, Ms. Zaim spent 20-plus years at Pfizer where she held diverse global positions encompassing global marketing, strategic planning, new business development and country management. She held a number of international assignments, including Asia Business Development Director based in Hong Kong and Country Manager of Thailand. Among her key roles at Pfizer were serving as Vice President of External Opportunities and New Business; Vice President of Commercial Development Primary Care Business Unit; Vice President, Medicine Team Leader; and

Group Leader, Neurosciences, Worldwide Marketing. During her career at Pfizer, she oversaw the global launches of several blockbuster products such as Spiriva, Lyrica and Eliquis. Ms. Zaim holds a Master of Business Administration degree from Columbia Business School, the business school of Columbia University located in Manhattan, New York City. She earned her

Bachelor of Science degree from the Rutgers School of Pharmacy.

Andrew Schorr, co-founder of PatientPower.info, is a medical journalist and pioneer in online education of patients with chronic conditions and cancer.

Since 1996 he has been a cancer patient himself, living with chronic lymphocytic leukemia and myelofibrosis. He has participated in two clinical trials and is an outspoken advocate for patients worldwide having access to state-of-the-art testing, treatments and clinical trials. Andrew’s company, Patient Power LLC, now reaches more than 140,000 cancer patients and family members each month. Often their efforts connect patients directly with pharma leaders to promote understanding and collaboration. Andrew is the author of the acclaimed book. “The Web-Savvy Patient”. He holds journalism degrees from the University of North Carolina and Columbia University.

Elena is VP, Head of Global Vaccine Commercial within Takeda Vaccines. Elena has joined Takeda in 2012 in a capacity of Global Head for Vaccine Business Operations and was directly involved in setting up this new global vaccine business. Originally, Elena is coming from Moldova where she got her degree in Management and Economics. For a few years after graduation Elena worked with European Commission in Eastern Europe and then moved to the US to get her MBA degree at the University of Chicago. After MBA she joined McKinsey, where she focused on healthcare sector. Prior to joining Takeda Elena also worked at Mead Johnson Nutrition and Hospira.

Meredith Hardy is the mother of Niels and Lachlan Strautnieks, two boys living with Mitochondrial Disease who receive treatment from a multidisciplinary team at the Children’s Hospital of Philadelphia. She works as a proactive advocate who documents observations, manages team communications, coordinates logistics, executes care plans, gathers research, and most importantly, pushes for outside of the box problem solving. As a result, her boys are changing how Mitochondrial Disease is treated. Known as a Children’s Hospital of Philadelphia success story on Facebook, Meredith has helped over 60 complex medical families build their multi-specialist medical care teams at CHOP. 

Peter Barschdorff oversees Commercial Insights generation, Brand Analytics, Advanced Analytics, Forecasting, Competitive Intelligence, and Enterprise Data Strategy at GSK’s U.S. Pharma business. A trained strategist, with stints at NATO, at the E.U., and in strategy consulting, he’s an executive with expansive knowledge and experience in commercial pharma, across a wide array of therapeutic areas. In previous roles at Bayer, he built an inhouse consulting team for Bayer’s North America, cross-divisional operations; led the global corporate effort of complexity reduction; and most recently directed the Business Insights department for the U.S. Pharma division. - Peter has an MBA from Columbia Business School, and a Ph.D. from the Free University of Berlin. In his spare time, he enjoys music, trains for the next marathon, and spends time with his family.

Jay is responsible for leading the U.S Professional Sales organization to include, the HCP Sales Force, Inside Sales, Global Pharma Trials, Sales Training, and Operations. 

Since joining Roche in 2006, Jay has held several positions within Diabetes Care to include Physician Field Sales Representative, Region Business Manager – Health Care Provider, Region Business Manager – Managed Care, Retail and Distribution, Area Business Director for the Central and Western US and Region Marketing Director for Blood Glucose Portfolio.   

Jay began his professional career in 1998 as an Intelligence Officer in the United States Army.  In the Army, Jay held multiple leadership positions and global deployments including tours in South America, Central America, The Caribbean, South Korea, The United Kingdom, Jordan and Iraq.  After leaving the Army, Jay worked as a Field Sales Representative in Sanofi-Aventis’ Metabolism Division before moving to Roche Diabetes Care.

A native of Raleigh, N.C., Jay earned a bachelor’s degree in Political Science and Military Science from North Carolina State University and is currently enrolled in the Executive MBA program at the University of North Carolina at Chapel Hill. 

More information coming soon...

Dr. Koenen is currently heading all cardiovascular development, as well as CV Medical within BMS.

Dr. Koenen joined BMS in 2011, and has worked in different medical and development functions in Europe, as well as in the US.

He joined BMS from Novo Nordisk, where his last position was Vice President and Head of Global Medical Affairs. During his 9 years with Novo Nordisk, Dr. Koenen had worked on the development of several compounds for Novo Nordisk, including three different insulin compounds, as well as launched several compounds successfully.

Before joining Novo Nordisk in 2002, Dr. Koenen worked for GlaxoSmithKline in London, UK, as well as in Germany. While at GlaxoSmithKline, Dr. Koenen was responsible for the development of anti-diabetic compounds. 

Dr. Koenen received his medical degree from Ruprecht-Karls University School of Medicine in Heidelberg, Germany, in 1994. He also holds a Master of Business Administration from Schiller International University.  In addition to attending Heidelberg Medical School, Dr. Koenen attended medical school in Johannesburg, South Africa; Basel, Switzerland; and Columbia, Missouri, USA.

As a board-certified internist and diabetologist, Dr. Koenen has researched the influence of ACE-Inhibitors on diabetic nephropathy, as well as the effect of insulin treatment on weight gain in obese type 2 diabetes patients.

Jerry Berger possesses over 20 years of IT marketing within the healthcare space.  He is currently the Senior Manager for Marketing for Samsung Healthcare where he markets mobility and wearable solutions to hospitals, long-term care, pharmas and consumer health organizations.   Prior to his current tenure at Samsung, he worked for Siemens Healthcare and marketed healthcare analytics and value-added services to the acute hospital space.   Jerry possesses an MBA from The American University in Washington DC.

More information coming soon...

More information coming soon...

Deb grew up in Green Bay, Wisconsin and graduated with her Master’s degree in Audiology from Memphis State University. After seven years practicing as a pediatric audiologist at Riley Hospital for Children in Indianapolis, Indiana, Deb and her husband relocated to South Carolina where she joined Eli Lilly and Company. She has been with Lilly for the past 18 years in sales and marketing, with the vast majority of her experience in marketing roles across both the US Affiliate and Global Brand Development. She possesses deep cardiovascular experience, extensive alliance experience, and she played a key role in the US launch of Effient. Deb was most recently the Senior Marketing Director of CIALIS, Strattera, Axiron and Puerto Rico within the US Bio-Medicine’s Business Unit, having P&L accountability for $2B+ of revenue. Most recently, she assumed the leadership role of a Multi-Channel Engagement cross-functional team that is leading the transformation of the go-to-market model for healthcare professionals across the three business units of the US Affiliate. Deb delivers strong results through building empowered, high achieving teams by focusing on individual development, accountability, and recognition. She has extensive experience developing and executing the health care provider marketing strategy and efforts both on the global and affiliate side of the business, including hospital experience and US product launch, amongst the therapeutic areas of cardiovascular, osteoporosis, and Men’s Health. She expanded her expertise to include robust direct to consumer marketing, payer marketing and contracting, and an expanded breadth of multi-channel marketing. Deb also engages in the marketing community by serving as a marketing facilitator within Lilly, and by serving as a guest lecturer at the Butler Lacey College of Business and Indiana University Kelly School of Business. She also serves on the board for Pharma Force and on the Strategic Marketing Board for the Lacey College of Business at Butler. Deb’s free time is dedicated to doing volunteer work for Helping Challenged Children, LLC, which provides medical equipment to children in need, and she volunteers throughout the year with her family. Her personal interests include playing volleyball, sketching, attending Green Bay Packers games as a loyal season ticket holder, cheering on the sidelines for her two very active children, and relaxing at the lake with her husband, kids, and friends.

Paul Gileno is a strong force in the chronic pain awareness movement. His mission in life is to empower and support those living with pain. Having pain himself makes the issue of pain care a personal and public matter for him. After a work injury in 2003 left him living with degenerative disc disease, failed back syndrome and complex regional pain syndrome for over three years, Paul created U.S. Pain Foundation.

As the integral force behind the U.S. Pain Foundation team, Paul is determined to improve healthcare and make a difference. He believes that by exploring new ways to cope, those with pain can find personal answers that enable them to grow and live once more with meaning and purpose. Furthermore, he is committed to making sure the public better understands the tolls and trials those with pain endure. He validates pain and empowers the 100 million Americans suffering to become educated and proactive.

Besides his work with U.S. Pain, Paul is on the Advisory Board for PainPathways magazine. He also supports various organizations that raise awareness and fund research on behalf of the chronic pain community, as all endeavors shift perceptions about pain and motivate change. In May 2014, he was the recipient of the Unsung Hero Award for his stellar work in pain policy initiatives as well as his significant contributions to advance the social awareness of pain and suffering. Paul additionally received the “2015 Educator of the Year Award” from the American Society of Pain Educators (ASPE).

More information coming soon...

Danielle Salowski leads the Health Industry Vertical at Facebook, where her team is focused on defining go-to-market strategies for advertising and innovation in the Health space. Facebook Health’s mission is to connect people to the information or services they need to improve lives and create better health outcomes. Prior to joining Facebook, Danielle spent 11 years in the Digital and Social Media space across various roles at Twitter, CafeMom and News Corp. Danielle graduated from Villanova University with a degree in Communication.

AJ and his team sit at the strategic core of GSK’s Innovation initiatives, company-wide. They are charged with charting a path to help guide the company’s growth through digital disruption of our current commercial model; including organic and inorganic value-creation opportunities. Further, they are tasked with devising digital innovation strategies and experiments for the Pharmaceutical and Vaccine businesses and have a charter to leverage resources across all GSK businesses, functions and geographies. The vision is quite simple. Make it easier for health care practitioners to treat patients by delivering breakthrough digital innovations that delight and deliver better outcomes for patients and payers.

Samir Shaikh works at the U.S. Food and Drug Administration (FDA) and serves as the Deputy Director for Patient Affairs in the Office of the Commissioner. Samir is responsible for enhancing patient engagement operations and expanding FDA’s public and private partnerships. These partnerships facilitate cross-agency policy making and are instrumental in incorporating patient perspective into regulatory decision making. Prior to the FDA, Samir conducted Epilepsy research at the University of Chicago Hospital and then joined Merck Pharmaceuticals as a Chemist in Alzheimer’s and Vaccines. Samir completed his undergraduate studies at the University of Chicago, has a Lean Six Sigma Black Belt, and is completing his M.B.A in Healthcare Management and Leading Organizations at Johns Hopkins University. 

Ms. Weirick is responsible for providing strategic direction and leadership in the areas of talent acquisition, culture and diversity & inclusion for AbbVie, a global biopharmaceutical company focused on discovering and delivering advanced innovative therapies that solve some of the world’s most challenging health problems. She joined AbbVie just prior to the company’s split from Abbott Laboratories in 2012 to lead a global team of recruiting, culture and D&I professionals. She is focused on creating an organization that delivers long-term, sustainable performance and attracts and retains the best talent in the marketplace. Prior to AbbVie, Weirick was Global Leader for Recruiting, Employer Branding and Onboarding Strategy at Cargill, an international producer and marketer of food, agricultural, financial and industrial products and services. She joined Cargill in 2009 as their North American Recruiting Leader. Prior to Cargill, Weirick was the Director of Talent Acquisition at Whirlpool Corporation. During her 12 years at Whirlpool, she focused on leading the talent acquisition function and developing their employer brand strategy for the global appliance manufacturer. She has held roles of increasing responsibility and directed multiple global HR initiatives in the areas of culture, employer branding, assessment, candidate management, onboarding, contingent workforce management and diversity & inclusion.

More information coming soon...

Samantha started with UCB in 2005 after several years in sales and marketing at Eli Lilly in the US and globally. She heads UCBCares US, a solution center that provides an exceptional caring experience, connecting patients to meaningful solutions regarding their disease and medication. Previously, Samantha headed a national Strategic Accounts team, who were focused on strategic business considerations within IDN’s, ACO’s and Super Groups. She has also been a regional director, marketing director, and district manager in Immunology at UCB, launching their first biologic.

Samantha is passionate about delivering value to patients in an ever-changing ecosystem of care. 

More information coming soon...

Tushar Parlikar is a Product Manager at Verily Life Sciences, LLC (and prior to that at Google Life Sciences, the predecessor of Verily Life Sciences), focused on Hardware & Medical Devices.  Tushar works in Verily's Cambridge Office.  Among other things, he is the Product Manager for Verily's investigational Study Watch device and involved in its deployment to clinical studies such as Verily's Baseline Study.  Tushar received an MS and PhD in Electrical Engineering from MIT.  His dissertation research was in the modeling and identification of the cardiovascular system, specifically estimating Cardiac Output from Blood Pressure. 

Scott leads our patient advocacy and engagement team as Vice President, Head of Global Patient Advocacy and Strategic Relationships. Prior to joining EMD Serono, Scott held leadership positions at the American Cancer Society Cancer Action Network and Men’s Health Network. Prior to his patient advocacy experience, Scott held positions in external relations at Sanofi Pasteur and was an analyst at PharmaStrat, a managed care market research company. Scott holds a M.P.A., Executive Leadership from the American University in Washington, D.C., and earned a B.A. cum laude in Political Science from Moravian College in Bethlehem, Pennsylvania. He is based in Washington, DC.

Kevin Cowles is the Vice President Neuroscience Sales for Shire Pharmaceuticals; he joined Shire in 2015 with a background of over 20+ years within the pharmaceutical industry. This background included working in leadership roles for Bausch + Lomb and AstraZeneca. Kevin started his career at Shire as the Great Lakes Region Zone Director. With Kevin’s proven track record of success in sales leadership within one year he was promoted to his current role as Vice President and is responsible for over 550+ sales reps with sales revenue of over $2 Billion.

He has a BA in Political Science from Western Kentucky University and a MS in Industrial & Engineering Technology from Murray State University. Kevin also spent 7 years in the United States Army as an officer, serving in various combat arms and combat support leadership positions. He retired in 1998 with rank of Captain.

Martha Orzechowski is the global lead for oncology patient group relations at AstraZeneca. She is responsible for developing and implementing global patient advocacy strategy, including support for national engagement. Prior to her role at AstraZeneca, Martha worked for the US & Global Government Affairs, Policy & Advocacy Teams at GSK, most recently as global respiratory advocacy lead. Martha is a passionate champion of patients and believes in the potential for industry-patient advocacy group relationships to transform healthcare outcomes.

Laurie Cooke is the CEO of HBA, a nonprofit dedicated to furthering the advancement and impact of women in healthcare. She was twice recognized as a PharmaVOICE 100 most inspiring people in life sciences, and Mentor of the Year by ASAE. Laurie’s career spans global roles across several industries and continents including the Project Management Institute’s executive management team, global pharma international teams, and hospital pharmacy. Laurie has a strong academic record with a BSc in Microbiology, an advanced scientific degree in Pharmacy, and a master’s in Software Engineering Management. She is a licensed Pharmacist and a Certified Association Executive.

More information coming soon...

John has spent the past 17 years focused on creating digital-centric customer experiences within the pharmaceutical industry. He has a passion for leading complex digital transformation programs from vision to launch and optimization. He has led successful marketing programs for all commercial audiences within pharma (Specialists, PCPs, Nurses, KOLs, Patients, Consumers, Payer and Public) across all channels.

Currently he is a Global Digital Channel Lead (Web & Mobile) at GlaxoSmithKline (GSK) within the Global Commercial Transformation team. In this role, he is driving efforts to improve GSK’s digital customer experience across a global set of channels. He has led the work on GSK’s HCP portal from strategy to launch in 70+ markets, with significant VOC and measurement improvements each year. He is also leading work streams on a mobile app, channel optimization and enhancements, disease state sites and digital governance. Previously as SVP Marketing at Digitas Health he led agency of record, and digital-centric client engagements for 10+ different pharmaceutical companies over a 12-year stretch. During this time, he spent two years leading an onsite team at AstraZeneca in work on new innovative

content partnerships with WebMD, MDLinx and ePocrates. Prior to joining the pharmaceutical industry John worked as a practicing environmental engineer, and held positions in consulting with McKinsey and Arthur D. Little. John’s educational background includes degrees in Engineering and International Business from Bucknell University along with an MBA in Strategy and Finance from the University of Maryland. https://www.linkedin.com/in/john-j-d-lineen-248819

More information coming soon...

Viseven delivers intelligent digital solutions for Pharma since 2009. We open new communication channels for Pharma and Life Sciences and enable in-field communication (face-to-face, email, remote) with interactive sales presentations, customer-facing apps, educational VR and AR content, etc. Our comprehensive solution, – eWizard platform – empowers Digital Content Factory, making a solid ground for multivendor environment for both creative agencies and Life Sciences companies and enables smooth organizational transformation. We focus on streamlined communication, cost reduction, speeded up time-to-market, transparency of budget allocation and prediction. 

Nataliya Andreychuk, chief executive officer at Viseven Group, is a leading expert in digital pharma marketing and Digital Content Factory implementation. She aims at delivering value for clients in the sphere of their business development at no outrageous costs, but with a good portion of quality and confidence. Nataliya empowers customers to improve their user experience, avoiding changing their business principals, but helping to develop and perfect them. Besides, she brings the eDetailing creation expertise to the new teams, unites them with the common ideas and beneficial goals by providing a clear vision and strategy of the new company development. Before joining the Viseven team, Nataliya had a strong background experience in marketing, business analytics and software development. Recently, she has been conducting a number of trainings and master-classes, sharing her expertise and participating in the most impactful healthcare, IT and marketing events.

Oksana is a leading expert in outbound and inbound pharma marketing strategy implementation. Being a resourceful and dedicated marketer, she takes care of each marketing campaign stage, starting with idea shaping and ending with efficiency analysis. Her expertise touches upon eDetailing production, remote calls with HCPs, personalized email marketing, VR/AR videos and apps production and promotion, and much more.

Ruslana is a skilled expert who has enabled the digital transformation of numerous global life sciences enterprises. She is capable of finding individual pathways towards improved digital organization management. Her expertise involves setting up digital eco-systems that reinforce the existing workflows, while providing ultimate scalability in work with branched content supply chains.

William King is the founder and Executive Chairman of Zephyr Health, the Insights-as-a-Service leader harnessing the power of global health data to help Life Sciences companies engage the right physicians, accounts, and institutions. He is passionate about creating innovative solutions to advance efficiency, strategy, and tactical problem solving for healthcare companies. Since its inception, Zephyr Health has grown to serve leading

pharmaceutical, biotech, medical device, and diagnostic companies globally, and has received numerous industry accolades, including being named one of Gartner’s “Cool Vendors in Life Science,” PM360’s “Most Innovative Start-ups,” and Insights Success’ “20 Most Valuable Enterprise Big Data Companies.” William himself was recognized as one of PharmaVOICE’s “100 Most Inspiring People” representing innovation and dedication to the healthcare industry, as well as one of PM360’s Elite. Prior to founding Zephyr Health, William held a range of global leadership positions in sales, marketing, training, and strategy at multinational Johnson & Johnson. He was also a member of the International Development Program for global leadership and people development. William is a regular participant at the industry’s most prestigious conferences including Big Data in BioMedicine, BIO International Convention, and Digital Healthcare Innovation Summit. He speaks on topics such as: 

• What You Need to Know About Creating a Big Data Strategy
• Unfashionably Late to the Big Data Party: How Biopharma Can Catch Up
• The Big Data Prescription for Pharma Marketing

William holds a Bachelor of Science in Business Administration from the University of Denver. He currently resides in the Bay Area with his wife and three children

With more than two decades of healthcare industry experience, Mark is known as an innovator among his clients and peers. He has spent the last 20 years in the agency world working in a broad range of therapeutic categories, from OTCs to oncology. The five years prior, Mark was in the device industry on the client side.

Mark is an expert in innovative programs for HCP and patient/consumer audiences. He has extensive strategic branding experience for both corporate and product-specific assignments. Mark has led a variety of high profile and successful inline, launch, and relaunch efforts within the US and globally.

Aimee Lenar, VP of Gastroenterology and Psychiatry, leads the strategic and investment decisions for two of Allergan’s largest business segments— the Gastroenterology (GI) and Psychiatry portfolios. She is also co-chair of the Allergan GI Governance Board, which is responsible for making global research and development decisions for Allergan’s GI and liver products.   Prior to this role, Ms. Lenar worked as a research and marketing executive for some of the most noted healthcare companies in the industry.   Over the span of her nearly two-decades in the industry, she has led numerous global marketing projects and product launches across various healthcare verticals, including CNS, women’s healthcare, and internal medicine, creating greater awareness among healthcare practitioners and consumers.  Prior to roles within the pharmaceutical industry, Ms. Lenar worked at the CDC’s National Center for Infectious Diseases. As a staple in the healthcare community, she is regularly called upon for her expertise and has been featured in numerous media outlets, including FiercePharma, Forbes, and Drug Store News, to name a few.  Ms. Lenar received her Bachelor of Arts degree in Anthropology from Princeton University followed by her Masters of Public Health from the Rollins School of Public Health at Emory University.  She resides in New Jersey with her husband and two children.

Robert Palmer is Chief Innovation Officer at HCB Health in Austin, Chicago and New Jersey. His 15+ years of DTC and HCP pharmaceutical experience followed 10 years of Consumer Package Goods experience. Before joining HCB Health, Robert was EVP, Managing Director for Digital and Video at Juice Pharma Worldwide. Prior experience includes Managing Partner at Sudler & Hennessey, overseeing Sudler's digital practice, and Managing Director of Tribal DDB New York, where he founded Tribal's healthcare practice with the online DTC consumer launch of Humira. He has also been a Partner at Rosetta, where he specialized in attitudinal segmentation and CRM. Robert is presently on the Advisory Board of the Digital Health Coalition, and is Chairman of the Medical Advertising Hall of Fame.

Bharti Rai is a results-driven leader with a 15 year history of career accomplishments within the Management Consulting and Pharmaceuticals Industry. Bharti currently works at Bayer Pharma, leading the Commercial Data Strategy, Governance, Data Operations and Reporting function. Prior to joining Bayer, Bharti worked in the Public Sector Practice at Deloitte Consulting. She has a versatile, cross-functional skillset encompassing Strategy, Sales & Marketing Operations, Data Strategy & Management, Process Reengineering, CRM and Digital Health. In addition Bharti brings a strong Business Development & Account Management track record. Her unique and broad operational experience lends itself to approaching Data and CRM challenges in a unique perspective

Martha leads Design Research for Fjord North America, the dedicated strategy, design and digital product development arm of Accenture Interactive. She has more than twenty years consulting experience, working as an applied ethnographer across multiple industries and collaborating with a range of practitioners including designers, engineers, business analysts, marcomms, and brand strategists. Prior to joining Fjord, she held leadership positions at gravitytank, HLB, Hall & Partners and Sapient. Martha is on the faculty of Northwestern University's MMM program--the Kellogg School of Management's marquee Design Thinking degree--where she developed and now teaches the Design Research curriculum.

A published author, Martha has spent her career studying how everyday people engage with products, services and brands, as well as helping her clients work differently and with a human-centered lens. She has conducted deep ethnographic research around the globe in many industries including healthcare and pharma.. As she helps her clients succeed in with their innovation portfolios, much of her work also includes a focus on corporate culture change and helping organizations learn how to get out of their own way so they can be successful in their innovation goals.

Over 15 years as a market researcher in the healthcare space, Jennifer has worked with with a wide range of commercial teams to identify and answer their most critical business questions. As co-developer of Trinity’s integrated Patient Journey approach, Jennifer works with commercial teams to build in-depth models of the “what’s” and “why’s” of patient treatment and management. Using a range of research methodologies and insights, Jennifer’s work ultimately helps clients understand how best apply Patient Journey insights to key commercial challenges. A qualitative market researcher at heart, Jennifer holds a B.A. in Psychology from Boston University.

Kevin is a thought leader with extensive experience focusing on patient-level data and analytics. As co-developer of Trinity’s analytics practice, Kevin leads an innovative team that supports commercial organizations throughout the life sciences industry. Drawing from the wide array of data sources applicable to the life sciences, Kevin and his analytics group provide compelling insights using secondary data. His areas of focus include market sizing, patient journey, patient adherence assessments, and Health Economics Outcomes Research (HEOR) studies. Prior to joining Trinity, Kevin received a B.S. in Managerial Economics and International Business from Bentley University.

Jeannie Joughin has also held various scientific positions including Senior Research Scientist, Post-Doctorate and Senior Post-Doctorate positions in Australia at The Alfred Hospital, The Walter & Eliza Hall Institute, as well as internationally in Austria (University Clinic, Innsbruck) and Switzerland (Ludwig Institute for Cancer Research, Lausanne). Dr. Joughin began her career in the pharmaceutical industry in 1992 as a Clinical Research Manager with Bristol-Myers Squibb. After managing local trials in oncology and cardiology, she moved into New Product Commercialisation as the interface between the medical and marketing departments. From there, Dr. Joughin worked in Brand Management. After successfully completing several marketing roles in the National Stroke Foundation, MediMark International and Mayne Pharma, Dr. Joughin joined CSL Biotherapies in 2005 as Director, Pharmaceuticals Marketing and In-licensing. She assumed responsibility for a portfolio of pharmaceutical products from several licensing partners in various therapeutic areas. Her responsibilities included extending distribution agreements with current partners when appropriate and securing various new product distribution agreements. As Vice President, Business Development at CSL Behring Dr Joughin was responsible for managing business licensing arrangements and relationships. This involved close liaison with CSL Behring’s Commercial Development Team in the US, Germany and Switzerland. Dr. Joughin joined Enable Injections as Vice President of Corporate Development in 2015 and now as Executive Vice President and Chief Commercial Officer she will support the CEO and Board with investment strategy and remains responsible for business development, strategic pharma partnerships, alliance management, as well as aiding in selection and prioritization of Enable Injections’ global portfolio.

More information coming soon...

Mahmood Majeed is a principal in ZS’s Evanston, Ill., office and leads the company’s global business technology practice area. For the past two decades, he has partnered with top Fortune 500 life sciences companies, advising them on commercial business transformation and enablement of analytics to drive commercial success. Mahmood holds an Executive MBA from Kellogg School of Management, a MS in Computer Science from DePaul University and BS in Architectural Design from University of Oklahoma.

ROLE 

Jérôme Chabrillat is an associate principal in ZS’s business technology practice. Jérôme leads ZS’s reporting and dashboard offerings globally, providing design and delivery expertise at scale across leading business intelligence technology solutions. He also leads the Personalized Analytics initiative, a ZS innovation that redefines how marketing and sales professionals consume business information in the AI age.

EXPERTISE

For the past 15 years, Jérôme has been designing and building technology solutions to address commercial problems ranging from sales force automation solutions to process automation and performance tracking. Clients value his creativity and innovative mindset, his deep understanding of technology solutions and ability to bring together business and technology stakeholders.

Beyond technology, Jérôme is also an expert in sales compensation administration, dramatically increasing payout quality, processing efficiency and speed.

PRIOR EXPERIENCE

Jérôme joined ZS in 2000 in our European offices as an associate and has since grown into a great people developer and technology thought leader.

EDUCATION

Jérôme holds a Bachelor of Science from the University of Brighton (UK). He has a passion for self-learning, having taken on design thinking, selling and marketing SaaS solutions, and several other topics.

Jean McCoy is SVP of Partnerships at Health Perspectives Group, a patient engagement and technology firm that helps companies integrate the authentic voice of real patients throughout all aspects of their business. Jean has over 25 years of biopharmaceutical commercialization experience and entrepreneurial business background. For more info: www.hpgroupllc.com

David Reim, Chief Product Officer at DMD, has been a leader in the digital marketing of healthcare products since he led the team that launched the first branded pharmaceutical website in 1995. David oversees the commercialization of all DMD products, from the industry’s No. 1 physician email database to the Audience Identity Manager (AIM) platform, named by PM360 magazine as one of the leading innovations of 2017.

More information coming soon...

More information coming soon...

Mark McKay enjoyed a meaningful and exciting 19 year pharma career in the field and in commercial operations for Abbott/Abbvie where he conducted over a thousand days of field coaching in his 12 years as a district manager. In his evangelizing role at MicroStrategy Mark now helps pharma leaders maximize the value of their data assets by adopting next-generation enterprise analytics and mobility solutions capable of transforming the field experience by increasing representative and manager efficiency, focus, and engagement in a constantly evolving environment.

Michael joined Southport Services Group in 2013, where he serves as a Managing Director, and for 3 years prior to that he was a Professional Services Director for MicroStrategy. Preceding his transition into account management was a 15-year career managing and delivering Business Intelligence and Decision Support System applications. His primary focus was on pharmaceutical sales and marketing offerings, most notably with ImpactRx, where he was responsible for the development of all client deliverable systems and the implementation of MicroStrategy. Michael brings value to life sciences engagements via his unique blend of pharma sales operations acumen and technical expertise.

As Vice President of Training, Tom has led Eagle Productivity Solutions through 18 years of successful change management and technology deployments around the globe. He has helped achieve the adoption of new skills as Eagle’s clients have migrated from the first handheld mobile devices to today’s robust, data rich tools. Tom’s prior experience in the broadcast industry has guided Eagles unique ability to “reach an audience” in both live and virtual classrooms. New analytic tools require a mindset change to achieve greater results in the field at a local business level and ensure market share success. Tom is honoured to host this track and discussions about the possibilities that lie ahead with new analytic insight!

Abigail Bernardi is Director of Market Planning at LexisNexis Risk Solutions – Health Care. For nearly 10 years, she has served as a subject matter expert on technical and business aspects of medical claims data management, research and development, compliance, claims analytics, and professional services for the Life Sciences and provider industries. Prior to LexisNexis Risk Solutions’ acquisition of Health Market Science in 2015, Bernardi served as Director of Professional Services there. She led all medical claims-related services and consulted on master data management topics including ICD/CPT coding, custom product solution architecture, and application of best practices. Bernardi holds a Bachelor of Science degree in Health Systems from Georgetown University in Washington, D.C.

Don is the Director of Business Development, and is responsible for the overall performance of the LexisNexis claims-based solutions. Don has over 20 years of experience in the healthcare industry, spanning roles in market research, sales, and account management. At LexisNexis, Don has responsibilities for business development and account management. He works with pharmaceutical, biotech, and medical device companies, as well as other health care-related organizations, to provide strategic consulting and information solutions to sales, commercial operations, and marketing, across the full range of LexisNexis Market Intelligence solutions. Prior to joining LexisNexis, Don was Sales Director at IMS Health, one of the world’s largest data and information companies in the pharmaceutical and healthcare industry. In this role, he supported numerous clients across multiple segments, including pharmaceutical and biotech companies, ad agencies, government agencies, consulting firms, and other health care-related organizations. Don holds a BS in Business from Stockton University, and an MBA in Pharmaceutical Marketing from St. Joseph’s University

Jeff Ford is a Principal in Deloitte Consulting LLP’s Life Science and Health Care Strategy practice where he focuses on helping clients overcome challenges related to growth and innovation. He regularly works with corporate leadership to identify new market opportunities, build new organizational models for growth, and transition between business models. In addition to his work at Deloitte, Jeff is on faculty at the University of California at Berkeley, Haas School of Business where he teaches the classes Commercialization of Biotechnology and Healthcare Finance to MBA students. Jeff holds an MBA and an MPH in Health Policy and Administration from the University of California at Berkeley.

Mike joined Ashfield, part of UDG Healthcare, plc in 2016 as the US leader for commercial and clinical services. Prior to Ashfield, Mike has worked at Mylan, Valeritas, and Sanofi in various sales and sales management roles. Under his leadership, his sales organizations have expanded in revenue as well as employees. During his time at Valeritas, Mike created a commercial sales organization for the start-up company. He spent 18 months as part of the commercial team to secure venture capital financing.

At a time when pharma is a convenient target for criticism, Doug Noland is helping lead a transformation in how the industry thinks and operates – driving empathetic patient-centered strategies across every phase of the discovery, development and commercialization process, and establishing new relationships across the healthcare spectrum. Doug created and heads the newly formed Astellas Patient Experience Organization, where he leads an exceptionally talented team whose mission is to establish Astellas as one of the most patient centered pharmaceutical companies in the world. In addition to building those internal capabilities, he is also collaborating with health systems, digital heath innovators and others with a shared goal of improving patient experiences and outcomes. He and his team are part of a growing movement to help the pharmaceutical industry do even more for patients – helping better their experiences, improve their outcomes, as well as change perceptions and enhance the reputation of the industry. Their business challenge is centered on succeeding in this dynamic, outcomes-focused healthcare environment by helping more patients and their families experience healthcare at its best through tangible and productive collaborations.

More information coming soon...

AJ has a 15-year career history in healthcare technology and communications with a track record of delivering innovative technology pilots in healthcare.  His understanding of how to navigate the tension between leading-edge innovation and regulatory compliance achieves results for clients and their customers.  

Leveraging his passion for UI/UX and connected health technology, AJ spent the last two and half years working closely with Apple and major academic research institutions and hospital systems to deliver mClincal research using Apple’s ResearchKit^TM and remote care programs using Apple’s CareKit^TM frameworks.  Innovative digital research and complementary service mHealth programs he helped bring to market are fundamentally changing the way healthcare is both researched and delivered in real time.

aj.triano@syneoshealth.com

More information coming soon...

Tara Cooke is Executive Director, IT Global Digital Program Lead for Novartis.  In this role she leads a cross-functional technology and data team partnering with the Chief Digital Officer to enable the Novartis digital strategy & transformation.  She is responsible for orchestrating delivery of core digital technology capabilities and services for the entire enterprise including IoT.   

She has a BA in Chemistry and Economics from Colgate University and an MBA in marketing and management from Rutgers business school. 

Jitesh Rohatgi - Pega’s global director and healthcare/life sciences principal, has over 15 years of experience advising life sciences and healthcare organizations on the most effective use of Customer Engagement, Master Data Management, and AI technologies to improve clinical safety and patient care. Always up for a healthy debate on how we can all work towards better health outcomes for everyone, he can be reached at https://www.linkedin.com/in/jrohatgi/

More information coming soon...

More information coming soon...

Dr. Yechiel Engelhard is an experienced executive and entrepreneur who has co-founded, managed and sold health-tech companies, and led global teams for over 15 years. He has managed the development of new technologies, software and hardware products, business strategies, and industry partnerships focusing on mobile and connected devices. In 2012, he co-founded Gecko Health Inc. which developed an innovative connected device, accompanying mobile app and cloud-based system to treat chronic respiratory diseases and which was acquired by Teva Pharmaceuticals in 2015. As part of Teva, Dr. Engelhard leads the global digital products’ commercial team as the Head of Digital Health in the Global Respiratory Medicines group.

More information coming soon...

Susan is a thought leader at Salesforce around the practical uses of artificial intelligence, machine learning, data analytics, etc. and helps drive business value for pharma industry commercial teams that need to sell more efficiently and effectively while building excellent customer relationships and experiences. 

This involves the integration of data that resides in CRM systems, service operations, real world data, and more, and provides both user-guided and automated learning patterns to bring intelligent insights and prescriptive analytics to everyone from field users to executives.

Jerry Barsz brings more than twenty years of pharmaceutical industry experience to his commercial leadership role at Pillsy. In his position for the Seattle based technology company he drives the strategic direction, market expansion and client development for life science manufacturers as well as specialty, mail order and retail pharmacies.

More information coming soon...

More information coming soon...

• Victoria has over 11 years of experience and is the ethnographic healthcare lead at Ipsos. She has a particular interest in patients, adherence and medical anthropology.
• Victoria is an ethnographic research specialist and has worked with a range of global clients (Lilly, Pfizer, Teva, GSK, ViiV, Shire, Amgen, Genzyme, Bayer, NHS).
• Victoria has published in a number of academic journals using ethnographic methodologies including papers in Dove Medical Press and Environment and Planning A.
• Victoria won two awards at the MRS Awards in 2012, ‘Best Overall Contribution’ and ‘Best Newcomer’ and two MRS Awards in 2014 for ‘Healthcare’ and the overall ‘Grand Prix’ award. She was also awarded the John Wheeler Award in 2015 at the BHBIA Conference for best workshop, using patient footage from a global psoriasis study.
• Victoria has lectured at Hult International Business School, EMLYON Business School and is a regular keynote speaker for the charity Kids in Museums.

Senior business and technology leader with broad experience delivering Commercial programs in the Pharmaceutical and Biotechnology industries. Unique blend of hands-on experience and executive management skills to develop strong business partnerships and long-term vision and strategy. 
 
Certified Project Management Professional and Lean Six Sigma Black Belt. 

With over 25 years of experience in the pharmaceutical industry, Peter leads the efforts of Alamo Pharma Services. Previously, he was in a series of progressing roles with Solvay Pharmaceuticals and Noven Pharmaceuticals. Peter then joined the leadership team at inVentiv Health as Executive Director of Specialty Sales Teams and progressed to the role of Chief Learning Officer. Peter joined Mission family of companies in June 2011 to build Alamo Pharma Services. He is currently on the faculty at Rutgers Business School, where he co-teaches Managing the Pharmaceutical Sales Force, a course in the Pharmaceutical MBA program.

Sunny is a highly motivated Entrepreneur Executive with a demonstrated ability to build and scale innovative solutions to engage physicians and patients. Driven by the core belief that all work should engage people and inspire action, Sunny blends EQ with IQ to frame choices and drive results. Prior to founding viihealth, Sunny spent 20 years in various commercial roles at Merck, where he developed the US multi-channel strategy and was responsible for building / integrating digital channels such as e-detailing, e-education, and e-mail. He pioneered integrated digital channel campaigns and built capabilities to drive customer experience and engagement. Sunny is a passionate champion of human-centric design and customer-centric differentiation. He holds a BA in Chemistry from Loyola Chicago and an MBA from the University of Iowa.

Russ Sieger, Sr. Director of Business Development, US - Russ leads Business Development and Customer Engagement efforts in the US. He brings over 18 years of dedicated life sciences experience and a broad range of industry knowledge of customer engagement, data integration/analytics/insights, product commercialization, patient adherence and access, customer engagement and multichannel expertise to the company. Prior to viihealth, Russ has held sales and marketing roles with IntegriChain, Quintiles/IMS Health, Aptilon, McKesson, and MediMedia Health.   Russ holds a bachelor’s degree in Business and Marketing from the University of Rhode Island and an MBA from the Fox School of Business, Temple University

More information coming soon...

More information coming soon...

More information coming soon...

I was born in December of 1953 in Philadelphia. My mother passed at the age of fifty three from Hodgkin’s Lymphoma. My father passed at the age of seventy of heart failure. I had three sisters; my middle sister succumbed to Glioblastoma in 2012. I am married thirty nine years with five children. I was a mechanical engineer for forty two years at AECOM in Princeton New Jersey. I traveled extensively for work at various remote sites around the United States. I worked ten years in the nuclear industry and ten years in the chemical demilitarization industry, destroying weapons of mass destruction. I was recently laid off in October of 2016.

I was diagnosed in January of 2005 after a previous diagnosis of sleep apnea and allergies. Finally, after wife’s urging, I went to Jefferson Hospital on New Year’s Day, 2005. At Jeff they took an X-ray and saw a 3” x 5” mass in my chest. I was diagnosed with Large B Cell Stage IIA Non-Hodgkin’s Lymphoma. I received eight chemo treatments then continued with twenty radiation treatments. After a series of PET/CT scans for the next few years I was considered in remission.

After my treatment and survival I became aware of my good fortune. I wanted to give back and reach out to others going through health problems.

At a Celebration of Life at Jefferson Hospital I was introduced to the Buddy Program at Jeff. This program provides support to help cancer patients recently diagnosed with what to expect and how to cope with the changes to come.

While in this program I also became involved with the NCQA - National Committee for Quality Assurance as a patient consultant for Patient-Centered Oncology Care Pilot Practice Collaborative. This program provided technical assistance to practices on how to involve patients and families in their efforts to implement patient-centered oncology care and was mentored by the late Ellen Stovall.

I have also been involved in the Health Mentor Program at Thomas Jefferson University In mentoring students from the Jefferson Medical College. I am on my fourth set of students.

I was invited to provide input for the Sidney Kimmel Cancer Center Cancer Support and Welcome Center at Jefferson Hospital in Philadelphia before its opening. They requested survivors’ comments at this groundbreaking center for patients and their caregivers. Jefferson is a NCI-designated Cancer Center Hospital. I volunteer there as a “Buddy”. I was a speaker and honored to assist in the ribbon cutting ceremony at the grand opening of the center. I am also a volunteer at Jefferson Hospital.

In June of 2016 I served as a committee member and speaker at the NCCS CPAT Symposium in Washington, DC. It was for the NCCS Planning Actively for HR 2846 Planning Actively for Cancer Treatment (PACT) Act. The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors. I also attended this symposium in June of 2017. This concentrated on the AHCA and doctor patient communications.

I am also a “Buddy” for the 4th Angel program conducted out of the Cleveland Clinic and started by Scott Hamilton, U.S. Olympic gold medalist. I became aware of this program while attending the

Cancer Support Community in Philadelphia of which I am also a member. This is similar to the program run at Jefferson Hospital.

I attended the ASCO Survivorship Symposium in San Diego January 2016 as a member and survivor / advocate. In fact, after recently being laid off from work, I declined a job offer in able to attend this symposium.

At the San Diego Symposium I met Andrew and Esther Schorr. They are the co-founders of Patient Power, an organization devoted to helping cancer patients or survivors and their families through knowledge, to get the best medicine and return to or maintain good health.

Through my association with Patient Power I was connected to eyeforpharma. I attended the eyeforpharma Data & Technology in Clinical Trials USA in Philadelphia February of 2017. In June of 2017 I was on the survivor/advocate panel at the eyeforpharma 8th Annual Oncology Market Access and Pricing USA 2017. I was the Lead on the Patient Panel at the Patient Summit USA 2017 and attended the 7th Annual Data, Evidence and Access Data Summit 2017 both in November.

I volunteer for American Association for Cancer Research (AACR) and Cancer Support Community Greater Philadelphia (CSCGP) at their various funding events. My association with AACR gives me an avenue to thank the people who give their time and money to assist AACR in raising funds. I like to have them put a face to the people they are helping combat this horrible disease. I attended the AACR Rally for Medical Research Capitol Hill Day for SKCC and was the Patient Advocate for the 2017 Rock ‘n’ Roll Marathon in September 2017. I did a radio interview at WOGL in Philadelphia with Dr. Karen Knudsen - Director of the Sidney Kimmel Cancer Center and Rick Buck - AACR Senior Director of Communications and Public Relations and a Facebook Live interview with Mitch Stoller - Executive Director of the AACR. I was also the Patient Advisor for the 2017 AACR Philadelphia Marathon in November 2017. I did a photo shoot, Facebook Live interview with Mitch Stoller, KYW Radio and NBC10 TV interviews for the race,

I am also active in the Cancer Support Community of Greater Philadelphia, CSCGP at the Suzanne Morgan Center at Ridgeland in Fairmont Park. There I attend seminars, listen to various speakers and volunteer at their various funding events. I also attend the monthly Men’s Survivor and Support breakfast.

I attended the Triage Cancer Conference in Morgantown, West Virginia in September 2017 and the National Comprehensive Cancer Network (NCCN) Patient Advocacy Summit in Washington, DC December 2017.

More information coming soon...

Stacia Kalinoski is an Emmy award-winning journalist. TV news took her to local stations in Nebraska, Oregon and Michigan, but seizures started popping up along the way. Stacia’s career took an unexpected turn in 2014, when she lost her job following a seizure. The worst day of her life eventually led to the best day, brain surgery to remove part of her right temporal lobe, the focus of her seizures.

As a journalist, documenting this experience was a natural decision. Stacia produced a documentary called Brainstorm, which premiered on Twin Cities PBS, then select PBS stations nationwide in November 2017. Her goal is to reduce the stigma of epilepsy through education, which she now does through speaking arrangements and screenings of Brainstorm.

http://www.brainstormdocumentary.com